|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0950 GBX | -5.00% |
|
-40.62% | -55.81% |
| 06-30 | Oxford BioDynamics Plc Reports Earnings Results for the Half Year Ended March 31, 2026 | CI |
| 06-30 | EARNINGS: Cake Box profit jumps; Oxford BioDynamics names new CEO | AN |
| Market Cap | 4.75M 5.41M 4.37M 4.08M 7.69M 515M 7.84M 52.62M 20.39M 253M 20.32M 19.88M 879M | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 9.61M 10.95M 8.85M 8.25M 15.55M 1.04B 15.87M 106M 41.24M 511M 41.12M 40.23M 1.78B | EV / Sales 2026 * |
5.18x | EV / Sales 2027 * | - |
| Free-Float |
90.13% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Oxford BioDynamics Plc
| 1 day | -5.00% | ||
| 1 week | -40.62% | ||
| Current month | -5.00% | ||
| 1 month | -48.65% | ||
| 3 months | -52.50% | ||
| 6 months | -55.81% | ||
| Current year | -55.81% |
| 1 week | 0.08 |  | 0.17 |
| 1 month | 0.08 | | 0.2 |
| Current year | 0.08 | | 0.34 |
| 1 year | 0.08 | | 0.78 |
| 3 years | 0.08 | | 52 |
| 5 years | 0.08 | | 62.8 |
| 10 years | 0.08 | | 278.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 64 | 2007-06-07 | |
Paul Stockdale
DFI | Director of Finance/CFO | - | 2017-09-14 |
Robert Heaton
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 2007-06-07 | |
Paul Stockdale
BRD | Director/Board Member | - | 2017-09-14 |
David Holbrook
BRD | Director/Board Member | 65 | 2019-04-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 11-09 | Free | Founder | 15,000,000 | 0.7663% | ||
| 11-09 | Free | Chairman | 4,400,000 | 0.2248% | ||
| 11-09 | Free | Executive/Senior Manager | 15,000,000 | 0.7663% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.00% | -40.62% | -68.33% | -99.31% | 5.69M | |
| -3.02% | +11.23% | -10.70% | -29.81% | 3.28B | |
| +1.28% | +9.01% | +2.77% | -84.11% | 1.9B | |
| +1.10% | +3.48% | -8.99% | +1.21% | 298M | |
| +3.04% | +3.46% | -43.38% | - | 51.01M | |
| Average | -0.57% | -3.58% | -25.73% | -53.00% | 1.11B | |
| Weighted average by Cap. | -1.36% | +8.26% | -6.35% | -47.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.86M 2.11M 1.71M 1.59M 3M 201M 3.06M 20.55M 7.96M 98.65M 7.94M 7.77M 343M | - |
| Net income | - | - |
| Net Debt | 4.86M 5.54M 4.48M 4.17M 7.86M 526M 8.02M 53.83M 20.86M 258M 20.79M 20.34M 899M | - |
Employees
41
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-01 | GBX 0.0950 | -5.00% | 61,845,284 |
| 26-06-30 | GBX 0.1000 | -33.33% | 179,417,689 |
| 26-06-29 | GBX 0.1500 | +11.11% | 34,982,936 |
| 26-06-26 | GBX 0.1350 | -21.51% | 33,691,633 |
| 26-06-25 | GBX 0.1720 | +7.50% | 56,964,351 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.000950GBP
Average target price
0.0100GBP
Spread / Average Target
+952.63%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OBD Stock
Select your edition
All financial news and data tailored to specific country editions
